Rowan Bioceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 28-07-2024
- Paid Up Capital ₹ 4.15 M
as on 28-07-2024
- Company Age 19 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.15 Cr
as on 28-07-2024
- Revenue 5.65%
(FY 2023)
- Profit 4.24%
(FY 2023)
- Ebitda -0.99%
(FY 2023)
- Net Worth 8.32%
(FY 2023)
- Total Assets 5.22%
(FY 2023)
About Rowan Bioceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.15 M.
The company currently has active open charges totaling ₹1.15 Cr.
Sangeeta Narang and Arun Narang serve as directors at the Company.
- CIN/LLPIN
U24232DL2005PTC132842
- Company No.
132842
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Feb 2005
- Date of AGM
28 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Rowan Bioceuticals Private Limited offer?
Rowan Bioceuticals Private Limited offers a wide range of products and services, including Common Disease Medicines, Anti Acne Drug, Anti Infective Drugs & Medicines, Antifungal Cream, Ointment & Powder, Antibacterial Drugs, Hair Care, Shampoo, Hair Growth Supplements.
Who are the key members and board of directors at Rowan Bioceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arun Narang  | Director | 09-Feb-2005 | Current |
| Sangeeta Narang | Director | 09-Feb-2005 | Current |
Financial Performance of Rowan Bioceuticals.
Rowan Bioceuticals Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 5.65% increase. The company also saw a slight improvement in profitability, with a 4.24% increase in profit. The company's net worth moved up by a moderate rise of 8.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rowan Bioceuticals?
In 2023, Rowan Bioceuticals had a promoter holding of 96.39% and a public holding of 3.61%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 11 Oct 2022 | ₹2.00 M | Open |
Others Creation Date: 11 Mar 2013 | ₹9.50 M | Open |
How Many Employees Work at Rowan Bioceuticals?
Rowan Bioceuticals has a workforce of 17 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rowan Bioceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rowan Bioceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
